Blogs

We are pleased to announce advancements in Alzheimer’s Disease research, stemming from the Phase 3 LUCIDITY trial!

We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s.

Neurology Diagnostics (NDx) is proud to have been selected for Lilly's ALZ 2 Trailblazer trial and has been seeing patients in this trial since July 2020. As part of the study, NDx has randomized 39 patients of the trial's >1700 patients

A new study in The Lancet Neurology has brought hope to both researchers and patients, as it presents a novel way to test for Parkinson's disease even before any symptoms show up.

Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.

Neurology Diagnostics is proud to announce our participation and enrollment of patients in the Eli Lilly Alzheimer's disease study recently reported in the New York Times.

October 17, 2023 - Neurology Diagnostics’ Role in Advancing Alzheimer’s Research: LUCIDITY Phase 3 Outcomes - NDX Research Clinic Updates - New Referral Process - Accepting New Patients

Neurology Diagnostics Newsletter Summary [date] Accepting new patients, streamlined referrals, FDA-approved Alzheimer's drug Leqembi, and upcoming clinical trials for Alzheimer's, CTE, and Parkinson's. Join us in advancing neurological care.

Neurology Diagnostics is proud to announce that their primary neurologist, Dr. Joel Vandersluis, has been selected as a 2023 Health Care Hero.

What is clinical research? How do we do it, why is it important, and how can you get involved?